Printer Friendly

ROBERTS PHARMACEUTICAL CORPORATION ACQUIRES FOUR PRESCRIPTION PRODUCTS FROM SEARLE CANADA INC.

 SKOKIE, Ill., and EATONTOWN, N.J., March 25 /PRNewswire/ -- Roberts Pharmaceutical Corporation (NASDAQ: RPCX) and Searle have completed an agreement providing Roberts with exclusive Canadian rights to four Searle products: Norpace(R)/Norpace(R) CR, anti-arrhythmic cardiovascular drugs, and Banthine(R)/Pro-Banthine(R), anti-spasmodic drugs used to treat a variety of gastrointestinal disorders. Terms of the transaction were not disclosed.
 According to Joseph T. Curti, M.D., Searle corporate executive vice president and president, North American Operations, new product approvals in Canada are the reason for the sale of these products to Roberts. Searle recently received approval for Arthrotec(R), an innovative non-steroidal anti-inflammatory drug, and Maxaquin(R), a powerful quinolone anti-infective. Another new drug, Ambien(TM), which offers a completely new approach to the treatment of insomnia, is awaiting approval in Canada.
 "With multiple new product approvals in Canada, Norpace, Norpace CR, Banthine and Pro-Banthine no longer fit with Searle strategic objectives," said Curti. "Throughout the 1990s worldwide, we will concentrate our resources on innovative, patented products with high growth potentials."
 Commenting on the acquisition, Dr. Robert A. Vukovich, chairman and chief executive officer of Roberts, said, "The addition of these important products to our Canadian portfolio fits nicely into our strategy to expand the operations of Roberts of Canada. The new products will serve to broaden our market share and increase our physician awareness in the Canadian prescription drug market. The acquisition of Pro-Banthine in Canada allows Roberts greater penetration into the North American market since the U.S. rights to this product were acquired this past December from Searle. Roberts' Canadian subsidiary, Roberts of Canada, will begin marketing these products as soon as possible."
 Searle is a research-based developer, manufacturer and marketer of prescription drugs worldwide. It is a wholly owned subsidiary of the Monsanto Company (NYSE: MTC).
 Roberts Pharmaceutical Corporation is an international pharmaceutical company focusing on the acquisition and development of high-potential, undervalued, late-stage development products and the acquisition of currently marketed prescription and non-prescription products.
 -0- 3/25/93
 /CONTACT: Jeffrey G. Newton of Searle, 708-470-6280; or Anthony P. Maris of Roberts Pharmaceuticals, 908-389-1182/
 (MTC RPCX)


CO: Roberts Pharmaceutical Corporation; Searle ST: Illinois, New Jersey IN: MTC SU: TNM

TS-LR -- NY042 -- 9564 03/25/93 11:47 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 25, 1993
Words:374
Previous Article:SANDOZ LTD. PROPOSES NEW BOARD MEMBERS; REPORTS 1992 RESULTS; CHANGES IN GROUP MANAGEMENT
Next Article:PENN CENTRAL CORPORATION ANNOUNCES QUARTERLY DIVIDEND
Topics:


Related Articles
IVAX CORPORATION ANNOUNCES THE ACQUISITION OF THREE BRAND NAME PHARMACEUTICAL PRODUCTS
ROBERTS PHARMACEUTICAL ACQUIRES THREE CURRENTLY MARKETED PRODUCT LINES FROM G.D. SEARLE
ROBERTS PHARMACEUTICAL ACQUIRES THREE CURRENTLY MARKETED PRODUCT LINES FROM G.D. SEARLE
SEARLE ACQUIRES 100 PERCENT OF ITALIAN JOINT VENTURES
ROBERTS PHARMACEUTICAL CORPORATION ANNOUNCES PRODUCT ACQUISITION AGREEMENT WITH BRISTOL-MYERS SQUIBB
ROBERTS PHARMACEUTICAL CORPORATION COMPLETES PRODUCT ACQUISITION FROM GLAXO CANADA INC.
ROBERTS PHARMACEUTICAL CORPORATION COMPLETES ACQUISITION OF U.S. AND CANADIAN PRODUCT LINES FROM BRISTOL-MYERS SQUIBB
ROBERTS PHARMACEUTICAL CORPORATION TO ACQUIRE NITRODISC ANTI-ANGINAL DRUG FROM G.D. SEARLE
ROBERTS PHARMACEUTICAL CORPORATION COMPLETES ACQUISITION OF U.S. NITRODISC PRODUCT LINE FROM SEARLE
Roberts Pharmaceutical Corporation to Acquire Searle's FDA/HPB Approved Manufacturing Facility From Monsanto Canada Inc.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters